Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: The patient-navigation program for Endometrial Cancer

This is a pilot feasibility study to enable intensive outreach for marginalized patients with endometrial cancer (EC). Rural residents as well as patients who self-identify as Black or African American patients with EC have higher mortality rates.

Official registry: https://clinicaltrials.gov/study/NCT07927244 · UNC Lineberger Comprehensive Cancer Center · enrollment listed as 50

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are The patient-navigation program. The registry lists allocation as na. This is a pilot feasibility study to enable intensive outreach for marginalized patients with endometrial cancer (EC).

They plan to enroll about 50 people at Chapel Hill. Taking part typically means following a program (exercise, therapy, diet, or an app) plus check-ins.

Official title (unrewritten)

Patient Navigation in Gynecologic Oncology: Improving Care Among Marginalized Endometrial Cancer Patients

Interventions: The patient-navigation program

Primary outcome (registry wording): Fidelity of the navigation intervention

Who it is for (from inclusion criteria)

  • Ages 18 Years to any
  • Women only
  • Age ≥ 18 years at the time of consent
  • Resides in a \>25 miles between a patient's home and University of North Carolina Hospital
  • patients who self-identify as Black or African American race
  • Newly diagnosed or recurrent diagnosis of endometrial cancer undergoing treatment planning at University of North Carolina

Public study contact (from the registry)

Kacee Little

919-984-0000

kacee_little@med.unc.edu

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

1 listed

Related recruiting trials in this snapshot

RecruitingPhase 2Bethesda, Maryland
Phase 2: testing Pembrolizumab (Keytruda) for Metastatic Colorectal Cancer

Background: The NCI Surgery Branch has developed an experimental therapy that involves taking white blood cells from patients' tumors, growing them in the laboratory in large numbers, and then giving the cells back to the patient. These cells are called Tumor Infiltrating Lymphocytes, or TIL and we have given this type of treatment to over 200 patients with melanoma.

NCT01174121 · Official ClinicalTrials.gov record · National Cancer Institute (NCI)

RecruitingNot a traditional drug phasePhoenix, Arizona
Not a traditional drug phase: Vaginal Fluid Collection for Endometrial Cancer

The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in vaginal fluid and 2) ovarian cancer (OC) in plasma and vaginal fluid.

NCT05051722 · Official ClinicalTrials.gov record · Mayo Clinic

FAQ about this NCT record

Is NCT07927244 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07927244?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07927244?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary